Pharma Manufacturers & Providers - HARE - HealthCare Analyst Report Romania

Home PharmaPharma Manufacturers & Providers

21-09-2015
NHIH published opinion with regard to reimbursed treatment approval

18-09-2015
NHIH President:Patients have to be 'educated' regarding generics

18-09-2015
The National Institute for Health and Care Excellence issues an appraisal consultation document

18-09-2015
NICE: Myeloma treatment from Novartis is currently being appraised

18-09-2015
NICE issues opinion regarding Eli Lilly's treatment of gastric cancer

18-09-2015
Daiichi Sankyo Company is launching a new drug TS23

17-09-2015
Newly issued report regarding how cancer affects the UK economy

17-09-2015
Minister of Health: Present clawback fee calculation method could be improved

17-09-2015
Govern: Reimbursement list update

17-09-2015
MoH: Pricing regulatory framework modified

17-09-2015
UK: Wider use for therapy for psoriasis i

17-09-2015
NICE: New information on biological therapies

17-09-2015
US ICER: New pricing for Entreso from Novartis

17-09-2015
The Minister of Health made a new statement regarding the reimbursed drug list

17-09-2015
NICE issues an appraisal consultation document

15-09-2015
US FDA has agreed to undertake a priority review of Takeda's ixazomib

15-09-2015
The first therapy for a mitochondrial disease available in Europe

14-09-2015
The European Commissioner Vytenis Andriukatis cautioned civil society representatives on the low level of vaccination in Romania

14-09-2015
The Romanian Parliament: legal activities concerning the amendment of Healthcare Law

11-09-2015
NHIH: Negotiations concluded for Hepatitis C

10-09-2015
Govern: Decision regarding the reimbursed medication

10-09-2015
IQWIG: Evaluation of secukinumab in plaque psoriasis

08-09-2015
New data shows relentless rise in hepatitis deaths

08-09-2015
EC: Cross-border Healthcare report highlights advances and efforts at EU and national levels

08-09-2015
EPIA: Biopharmaceutical industry files complaint against French law promoting government-initiated off-label use without the involvement or consent of patients and their physicians

« Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 Next »

Advanced Search

Special Report

In an unexpected move, just before the end of 2011, ...

Case Study

Improving expenditure efficiency has been, for a ver...

Your Portal Link to Mass Media Universe.

Valuable Quarterly Romanian Market Analysis.

Ask the analyst

Tailor-made advice for you

Feature Company